Biogen, Eisai discontinuing aducanumab studies in AD

By Paul Bonanos, Assistant Editor | Mar 21, 2019 | 12:30 PM GMT

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more pressure on Biogen to add to its Phase III pipeline.

The companies

Read the full 468 word article

How to gain access

Continue reading with a
two-week free trial.